{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:42:07Z","timestamp":1790412127601,"version":"4.1.0"},"reference-count":123,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Inflammatory bowel diseases (IBDs), mainly represented by Crohn\u2019s disease (CD) and Ulcerative Colitis (UC), are chronic disorders with an unclear pathogenesis. This incurable and iterative intestinal mucosal inflammation requires the life-long use of anti-inflammatory drugs to prevent flares or relapses, which are the major providers of complications, such as small bowel strictures and intestinal perforations. The introduction of tumor necrosis factor (TNF)-alpha inhibitors and other compounds, such as anti-IL12\/23 and anti-alpha4\/beta7 integrin monoclonal antibodies, has considerably improved the clinical management of IBDs. They are now the standard of care, being the first-line therapy in patients with aggressive disease and in patients with moderate to severe disease with an inadequate response to conventional therapy. However, for approximately one third of all patients, their efficacy remains insufficient by a lack or loss of response due to the formation of anti-drug antibodies or compliance difficulties with parenteral formulations. To address these issues, orally administered Small Molecules Drugs (SMDs) that use a broad range of novel pharmacological pathways, such as JAK inhibitors, sphingosine-1-phosphate receptor modulators, and phosphodiesterase 4 inhibitors, have been developed for CD and UC. This article provides an updated and complete review of the most recently authorized SMDs and SMDs in phase II\/III development.<\/jats:p>","DOI":"10.3390\/ph14070637","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T02:44:39Z","timestamp":1625107479000},"page":"637","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Small Molecule Drugs in Inflammatory Bowel Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"In\u00e8s","family":"Ben Ghezala","sequence":"first","affiliation":[{"name":"INSERM, CIC1432, Plurithematic Unit, 21079 Dijon, France"},{"name":"Clinical Investigation Center, Plurithematic Unit, Dijon Bourgogne University Hospital, 21079 Dijon, France"},{"name":"Ophthalmology Department, Dijon Bourgogne University Hospital, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebva","family":"Charkaoui","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dijon Bourgogne University Hospital, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Michiels","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, Dijon Bourgogne University Hospital, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bardou","sequence":"additional","affiliation":[{"name":"INSERM, CIC1432, Plurithematic Unit, 21079 Dijon, France"},{"name":"Clinical Investigation Center, Plurithematic Unit, Dijon Bourgogne University Hospital, 21079 Dijon, France"},{"name":"Gastroenterology Department, Dijon Bourgogne University Hospital, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-293X","authenticated-orcid":false,"given":"Maxime","family":"Luu","sequence":"additional","affiliation":[{"name":"INSERM, CIC1432, Plurithematic Unit, 21079 Dijon, France"},{"name":"Clinical Investigation Center, Plurithematic Unit, Dijon Bourgogne University Hospital, 21079 Dijon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","article-title":"Inflammatory bowel disease: Clinical aspects and established and evolving therapies","volume":"369","author":"Baumgart","year":"2007","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrgastro.2013.117","article-title":"Extraintestinal manifestations and complications in IBD","volume":"10","author":"Ott","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"ref_4","unstructured":"(2020). The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol., 5, 17\u201330."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.5009\/gnl19019","article-title":"Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease","volume":"13","author":"Na","year":"2019","journal-title":"Gut. Liver."},{"key":"ref_6","unstructured":"Ganellin, R., Roberts, S., and Jefferis, R. (2013). Chapter 5-Similarities and differences in the discovery and use of biopharmaceuticals and small-molecule chemotherapeutics. Introduction to Biological and Small Molecule Drug Research and Development, Elsevier."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/MCG.0000000000000660","article-title":"World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015","volume":"50","author":"Bernstein","year":"2016","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_9","first-page":"413","article-title":"Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn\u2019s disease?","volume":"31","author":"Tsui","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","article-title":"Conventional medical management of inflammatory bowel disease","volume":"140","author":"Burger","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMct1209614","article-title":"Tumor necrosis factor inhibitors for inflammatory bowel disease","volume":"369","author":"Nielsen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1136\/gutjnl-2017-315494","article-title":"Cell-centred meta-analysis reveals baseline predictors of anti-TNF\u03b1 non-response in biopsy and blood of patients with IBD","volume":"68","author":"Gaujoux","year":"2019","journal-title":"Gut"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/CEG.S4512","article-title":"The impact of biologics on health-related quality of life in patients with inflammatory bowel disease","volume":"2","author":"Vogelaar","year":"2009","journal-title":"Clin. Exp. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ecco-jcc\/jjw002","article-title":"Non-adherence to Anti-TNF Therapy is Associated with Illness Perceptions and Clinical Outcomes in Outpatients with Inflammatory Bowel Disease: Results from a Prospective Multicentre Study","volume":"10","author":"Oldenburg","year":"2016","journal-title":"J. Crohns. Colitis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1080\/17425255.2017.1292251","article-title":"Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: Implications for biologics-small molecule drug interactions","volume":"13","author":"Mallick","year":"2017","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.06.007","article-title":"Involvement of JAK\/STAT signaling in the pathogenesis of inflammatory bowel disease","volume":"76","author":"Coskun","year":"2013","journal-title":"Pharm. Res"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stemcr.2017.11.015","article-title":"JAK\/STAT-1 Signaling Is Required for Reserve Intestinal Stem Cell Activation during Intestinal Regeneration Following Acute Inflammation","volume":"10","author":"Richmond","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/B978-0-444-62652-3.00004-1","article-title":"Advances in the discovery of selective JAK inhibitors","volume":"52","author":"Menet","year":"2013","journal-title":"Prog. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/MEG.0000000000001730","article-title":"Small molecule drugs in the treatment of inflammatory bowel diseases: Which one, when and why?\u2014A systematic review","volume":"32","author":"Lucaciu","year":"2020","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: Results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Sandborn","year":"2017","journal-title":"Gut"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of Upadacitinib in a Randomized Trial of Patients with Active Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients with Crohn\u2019s Disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_27","unstructured":"(2021, February 22). A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Moderately to Severely Active Crohn\u2019s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345836."},{"key":"ref_28","unstructured":"(2021, February 22). Filgotinib in the Induction and Maintenance of Remission in Adults with Moderately to Severely Active Ulcerative Colitis (SELECTION1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914522."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): Results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_30","unstructured":"(2021, February 22). A Phase II Study in Patients with Moderate to Severe Active Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03675477."},{"key":"ref_31","unstructured":"(2021, February 22). A Phase II Study in Patients with Moderate to Severe Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03677648."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results from a Randomised, Phase 2 Study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_33","unstructured":"(2021, February 22). Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02958865."},{"key":"ref_34","unstructured":"(2021, February 22). Study to Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects with Moderate To Severe Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03395184."},{"key":"ref_35","unstructured":"(2021, February 22). A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04613518."},{"key":"ref_36","unstructured":"(2021, February 22). An Investigational Study of Experimental Medication BMS-986165 in Participants with Moderate to Severe Crohn\u2019s Disease, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03599622."},{"key":"ref_37","unstructured":"(2021, February 22). Efficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03758443."},{"key":"ref_38","unstructured":"(2021, February 22). Efficacy and Safety of TD-1473 in Crohn\u2019s Disease (DIONE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03635112."},{"key":"ref_39","unstructured":"(2021, February 22). Study of OST-122 in Patients with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04353791."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2468-1253(20)30188-6","article-title":"Ozanimod induction therapy for patients with moderate to severe Crohn\u2019s disease: A single-arm, phase 2, prospective observer-blinded endpoint study","volume":"5","author":"Feagan","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): A phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1136\/gutjnl-2016-313457","article-title":"Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn\u2019s disease: Report of the OPERA study","volume":"67","author":"Sandborn","year":"2018","journal-title":"Gut"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.gastro.2006.11.029","article-title":"A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis","volume":"132","author":"Schreiber","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1016\/j.cgh.2019.12.032","article-title":"Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients with Active Ulcerative Colitis","volume":"18","author":"Danese","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1407250","article-title":"Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn\u2019s disease","volume":"372","author":"Monteleone","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_48","unstructured":"(2021, May 18). Phase 2 Dose-finding IMU-838 for Ulcerative Colitis (CALDOSE-1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03341962."},{"key":"ref_49","unstructured":"(2021, May 18). Safety Evaluation of ABX464 in Patients with Moderate to Severe Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03905109."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Vermeire, S., H\u00e9buterne, X., Tilg, H., De Hertogh, G., Gineste, P., and Steens, J.M. (2021). Induction and Long-term Follow-up with ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial. Gastroenterology.","DOI":"10.1053\/j.gastro.2021.02.054"},{"key":"ref_51","unstructured":"(2021, May 18). Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03861143."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"G155","DOI":"10.1152\/ajpgi.00311.2015","article-title":"JAK inhibition using tofacitinib for inflammatory bowel disease treatment: A hub for multiple inflammatory cytokines","volume":"310","author":"Danese","year":"2016","journal-title":"Am. J. Physiol Gastrointest Liver Physiol"},{"key":"ref_53","unstructured":"(2021, February 19). Highlights of prescribing information. XELJANZ, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/203214s024,208246s010lbl.pdf."},{"key":"ref_54","unstructured":"(2021, February 19). Xeljanz. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xeljanz."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cgh.2018.07.009","article-title":"Tofacitinib Induction Therapy Reduces Symptoms within 3 Days for Patients with Ulcerative Colitis","volume":"17","author":"Hanauer","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/apt.15555","article-title":"Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: Results from OCTAVE Open","volume":"51","author":"Sands","year":"2020","journal-title":"Aliment. Pharm."},{"key":"ref_57","unstructured":"(2021, February 19). A Study of Tofacitinib in Patients with Ulcerative Colitis in Stable Remission, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03281304."},{"key":"ref_58","unstructured":"(2021, February 19). Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering from Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04624230."},{"key":"ref_59","unstructured":"(2021, February 21). Xeljanz and Healthy Diet, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505410."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Pan\u00e9s, J., Su, C., Bushmakin, A.G., Cappelleri, J.C., Mamolo, C., and Healey, P. (2015). Randomized trial of tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes. BMC Gastroenterol., 15.","DOI":"10.1186\/s12876-015-0239-9"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Vong, C., Martin, S.W., Deng, C., Xie, R., Ito, K., Su, C., Sandborn, W.J., and Mukherjee, A. (2021). Population Pharmacokinetics of Tofacitinib in Patients with Moderate to Severe Ulcerative Colitis. Clin. Pharm. Drug Dev.","DOI":"10.1002\/cpdd.899"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1111\/apt.15514","article-title":"Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme","volume":"50","author":"Sandborn","year":"2019","journal-title":"Aliment. Pharm."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Curtis, J.R., Regueiro, M., Yun, H., Su, C., DiBonaventura, M., Lawendy, N., Nduaka, C.I., Koram, N., Cappelleri, J.C., and Chan, G. (2020). Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data from the IBM MarketScan\u00ae Administrative Claims Database with Tofacitinib Trial Data. Inflamm. Bowel. Dis.","DOI":"10.1093\/ibd\/izaa289"},{"key":"ref_65","unstructured":"(2021, February 21). Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects with Rheumatoid Arthritis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02092467."},{"key":"ref_66","unstructured":"(2021, February 21). Increased Risk of Blood Clots in Lungs and Death with Higher Dose of Xeljanz (tofacitinib) for Rheumatoid Arthritis. Available online: https:\/\/www.ema.europa.eu\/en\/news\/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_68","unstructured":"(2021, February 21). Initial Safety Trial Results Find Increased Risk of Serious Heart-Related Problems and Cancer with Arthritis and Ulcerative Colitis Medicine Xeljanz, Xeljanz XR (tofacitinib), Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/initial-safety-trial-results-find-increased-risk-serious-heart-related-problems-and-cancer-arthritis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data from Global Clinical Trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Panaccione, R., Isaacs, J.D., Chen, L.A., Wang, W., Marren, A., Kwok, K., Wang, L., Chan, G., and Su, C. (2020). Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig. Dis. Sci.","DOI":"10.1007\/s10620-020-06560-4"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/apt.15072","article-title":"Long-term safety and tolerability of oral tofacitinib in patients with Crohn\u2019s disease: Results from a phase 2, open-label, 48-week extension study","volume":"49","author":"Higgins","year":"2019","journal-title":"Aliment. Pharm."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40262-017-0605-6","article-title":"Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials","volume":"57","author":"Mohamed","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_73","unstructured":"(2021, February 21). A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants with Moderately to Severely Active Ulcerative Colitis (UC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02819635."},{"key":"ref_74","unstructured":"(2021, February 21). A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Moderately to Severely Active Ulcerative Colitis (U-Accomplish), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03653026."},{"key":"ref_75","unstructured":"(2021, February 21). A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants with Ulcerative Colitis (UC), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03006068."},{"key":"ref_76","unstructured":"(2021, February 21). A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants with Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02782663."},{"key":"ref_77","unstructured":"(2021, February 22). A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants with Moderately to Severely Active Crohn\u2019s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and\/or Biologic Therapies, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345849."},{"key":"ref_78","unstructured":"(2021, February 22). A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants with Crohn\u2019s Disease Who Completed the Studies M14-431 or M14-433, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03345823."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40262-015-0240-z","article-title":"Pharmacokinetics and Pharmacokinetic\/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection","volume":"54","author":"Namour","year":"2015","journal-title":"Clin. Pharm."},{"key":"ref_80","unstructured":"(2020, October 12). Phase 2b\/3 Trial Shows Efficacy of Filgotinib for the Induction and Maintenance of Remission in Moderately and Severely Active Ulcerative Colitis. Available online: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/10\/phase-2b3-trial-shows-efficacy-of-filgotinib-for-the-induction-and-maintenance-of-remission-in-moderately-and-severely-active-ulcerative-colitis."},{"key":"ref_81","unstructured":"(2021, February 22). Filgotinib in Long-Term Extension Study of Adults with Ulcerative Colitis (SELECTIONLTE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914535."},{"key":"ref_82","unstructured":"(2021, February 22). Filgotinib in the Induction and Maintenance of Remission in Adults with Moderately to Severely Active Crohn\u2019s Disease (Diversity1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914561."},{"key":"ref_83","unstructured":"(2021, February 22). Filgotinib in Long-Term Extension Study of Adults with Crohn\u2019s Disease (DIVERSITYLTE), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914600."},{"key":"ref_84","unstructured":"(2021, February 22). Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn\u2019s Disease (SBCD) (Divergence1), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03046056."},{"key":"ref_85","unstructured":"(2021, May 18). Assessment report Jyseleca. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/jyseleca-epar-public-assessment-report_en.pdf."},{"key":"ref_86","unstructured":"(2021, May 18). Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis. Available online: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/8\/gilead-receives-complete-response-letter-for-filgotinib-for-the-treatment-of-moderately-to-severely-active-rheumatoid-arthritis."},{"key":"ref_87","unstructured":"(2021, February 22). Study to Evaluate the Testicular Safety of Filgotinib in Adult Males with Moderately to Severely Active Inflammatory Bowel Disease (MANTA), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03201445."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1136\/annrheumdis-2015-208279","article-title":"Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: A 12-week, randomised, double-blind, placebo-controlled phase IIb study","volume":"75","author":"Takeuchi","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_90","unstructured":"(2021, February 02). Bristol Myers Squibb Announces Positive Topline Results from Second Pivotal Phase 3 Psoriasis Study Showing Superiority of Deucravacitinib Compared to Placebo and Otezla\u00ae (apremilast). Available online: https:\/\/news.bms.com\/news\/details\/2021\/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Second-Pivotal-Phase-3-Psoriasis-Study-Showing-Superiority-of-Deucravacitinib-Compared-to-Placebo-and-Otezla-apremilast\/default.aspx."},{"key":"ref_91","unstructured":"(2021, February 22). Safety and Efficacy of BMS-986165 in Participants with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03934216."},{"key":"ref_92","unstructured":"(2021, February 22). TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03920254."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4062\/biomolther.2016.160","article-title":"Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery","volume":"25","author":"Park","year":"2017","journal-title":"Biomol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/ibd\/izy269","article-title":"Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts","volume":"25","author":"Tyler","year":"2019","journal-title":"Inflamm. Bowel. Dis."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Christopher","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharm."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Sandborn, W.J., Feagan, B.G., Hanauer, S., Vermeire, S., Ghosh, S., Liu, W.J., Petersen, A., Charles, L., Huang, V., and Usiskin, K. (2021). Long-Term Efficacy and Safety Of Ozanimod In Moderate-To-Severe Ulcerative Colitis: Results From The Open-Label Extension Of The Randomized, Phase 2 Touchstone Study. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjab012"},{"key":"ref_98","unstructured":"(2021, March 23). Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03440372."},{"key":"ref_99","unstructured":"(2021, March 23). Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03440385."},{"key":"ref_100","unstructured":"(2021, March 22). A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03464097."},{"key":"ref_101","unstructured":"(2021, March 22). An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn\u2019s Disease, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03467958."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Vermeire, S., Chiorean, M., Pan\u00e9s, J., Peyrin-Biroulet, L., Zhang, J., Sands, B.E., Lazin, K., Klassen, P., Naik, S.U., and Cabell, C.H. (2021). Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjab016"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","article-title":"Anti-integrin therapy for inflammatory bowel disease","volume":"24","author":"Park","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_104","first-page":"Cd006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Modi, N.B., Cheng, X., Mattheakis, L., Hwang, C.C., Nawabi, R., Liu, D., and Gupta, S. (2021). Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of \u03b14\u03b27, in Healthy Volunteers. Clin. Pharm. Drug Dev.","DOI":"10.1002\/cpdd.946"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/13543784.2018.1494722","article-title":"PF-00547659 for the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"27","author":"Allocca","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Reinisch, W., Sandborn, W.J., Danese, S., H\u00e9buterne, X., K\u0142opocka, M., Tarabar, D., Va\u0148\u00e1sek, T., Gregu\u0161, M., Hellstern, P.A., and Kim, J.S. (2021). Long-term safety and efficacy of the anti-MAdCAM-1 monoclonal antibody ontamalimab (SHP647) for the treatment of ulcerative colitis: The open-label study TURANDOT II. J. Crohns Colitis.","DOI":"10.1093\/ecco-jcc\/jjab023"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Spadaccini, M., D\u2019Alessio, S., Peyrin-Biroulet, L., and Danese, S. (2017). PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue. Int. J. Mol. Sci, 18.","DOI":"10.3390\/ijms18061276"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1038\/mi.2008.55","article-title":"TGF-beta1 and Smad7 in the regulation of IBD","volume":"1","author":"Monteleone","year":"2008","journal-title":"Mucosal. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1053\/j.gastro.2006.09.016","article-title":"Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis","volume":"131","author":"Boirivant","year":"2006","journal-title":"Gastroenterology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"738","DOI":"10.14309\/ajg.0000000000000493","article-title":"Mongersen (GED-0301) for Active Crohn\u2019s Disease: Results of a Phase 3 Study","volume":"115","author":"Sands","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"102129","DOI":"10.1016\/j.msard.2020.102129","article-title":"Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis","volume":"43","author":"Muehler","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40268-019-00286-z","article-title":"The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study","volume":"19","author":"Muehler","year":"2019","journal-title":"Drugs R D"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s13318-020-00623-7","article-title":"Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects","volume":"45","author":"Muehler","year":"2020","journal-title":"Eur. J. Drug Metab. Pharm."},{"key":"ref_115","unstructured":"Immunic, Inc. (2020, November 04). Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis. Available online: https:\/\/www.immunic-therapeutics.com\/2020\/08\/02\/immunic-inc-reports-positive-top-line-data-from-phase-2-emphasis-trial-of-imu-838-in-patients-with-relapsing-remitting-multiple-sclerosis\/."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41598-018-37813-y","article-title":"Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing","volume":"9","author":"Vautrin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_117","unstructured":"(2021, May 18). Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients with Moderate to Severe Ulcerative Colitis, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023396."},{"key":"ref_118","first-page":"643","article-title":"The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial","volume":"26","author":"Leber","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s40273-020-00961-z","article-title":"Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China","volume":"38","author":"Tian","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1007\/s10067-020-05087-3","article-title":"Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain","volume":"39","author":"Navarro","year":"2020","journal-title":"Clin. Rheumatol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm Res."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Mancina, R.M., Pagnotta, R., Pagliuso, C., Albi, V., Bruno, D., Garieri, P., Doldo, P., and Spagnuolo, R. (2020). Gastrointestinal Symptoms of and Psychosocial Changes in Inflammatory Bowel Disease: A Nursing-Led Cross-Sectional Study of Patients in Clinical Remission. Medicina, 56.","DOI":"10.3390\/medicina56010045"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/7\/637\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:24:11Z","timestamp":1760163851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/14\/7\/637"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":123,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["ph14070637"],"URL":"https:\/\/doi.org\/10.3390\/ph14070637","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]}}}